Heart safety of asthma drug tezepelumab under scrutiny in massive study

NCT ID NCT06951867

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study tracks over 16,000 teens and adults with severe asthma to see if the drug tezepelumab raises the risk of serious heart problems like heart attack, stroke, or heart-related death. Researchers will compare those taking tezepelumab to those on standard asthma treatments. The goal is to better understand the drug's heart safety in real-world use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tezepelumab (brand name TEZSPIRE)
What this could lead to: If it shows tezepelumab is safe for the heart, it could reassure patients and doctors that this asthma treatment does not increase cardiovascular risk.
What could go wrong: This is an observational study, not a controlled trial, so it can only suggest links, not prove cause and effect. Results may be influenced by other factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR EVENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic asthma coronary artery disorder heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR EVENTS MACE

Contacts and locations

Locations

Danish registries (access/analysis)
RECRUITING

Copenhagen, Denmark
French National Health Data System (SNDS)
RECRUITING

Paris, France
Healthcare Integrated Research Database (HIRD)
RECRUITING

Wilmington, Delaware, 19801, United States
Team Gesundheit GKV Claims data (SHI)
RECRUITING

Berlin, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.